정규장
로그인 회원가입
RVMD
Revolution Medicines Inc
7월 27일 12:37 PM ET (한국 7/28 01:37)
$189.23
+0.48 ▲ +0.25%

레볼루션 메디신즈(RVMD) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$40.2B
미드캡
P/E
-
배당수익률
없음
52주 위치
97%
저점 +457% · 고점 -2%
애널리스트
적극 매수
C
Fundamental health
vs. 초고성장주 대형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 72%
밸류에이션
데이터 부족
재무 안정
Top 48%
Index -P/E -EPS (ttm) -7.07Insider Own 10.58%Shs Outstand 200.2MPerf Week 1.65%
Market Cap 40.23BForward P/E -EPS next Y 33%Insider Trans -1.68%Shs Float 190.1MPerf Month 11.46%
Enterprise Value 38.76BPEG -EPS next Q -2.04Inst Own 86.32%Short Float 6.78%Perf Quarter 40.71%
Income -1.37BP/S -EPS this Y -32.92%Inst Trans -0.31%Short Ratio 4.48Perf Half Y 59.27%
Sales 0.00BP/B 25.25EPS next 5Y 44.87%ROA -59.39%Short Interest 12.88MPerf YTD 137.58%
Book/sh 7.49P/C 21.08EPS past 3/5Y -24.48% -29.13%ROE -76.67%52W High -2.37% ($193.82)Perf Year 408.41%
Cash/sh 8.98P/FCF -Sales past 3/5Y -ROIC -71.42%52W Low 456.56% ($34.00)Perf 3Y 629.49%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM -76.93%Gross Margin -Volatility(W/M) 4.92% 4.16%Perf 5Y 553.87%
Dividend TTM -EV/Sales -Sales Y/Y TTM -100%Oper. Margin -ATR (14) 7.13Perf 10Y -
Dividend Ex-Date -Quick Ratio 6.8EPS Q/Q -101.97%Profit Margin -RSI (14) 61.96Recom 1.1
Dividend Gr. 3/5Y -Current Ratio 6.8Sales Q/Q -SMA20 1.45% ($186.53)Beta 1.39Target Price $207.16
Payout -Debt/Eq 0.29Earnings 2026/5/6SMA50 12.84% ($167.7)Rel Volume 0.43Prev Close $188.75
Employees 883LT Debt/Eq 0.28EPS/Sales Surpr. -24.75% -100%SMA200 68.99% ($111.98)Avg Volume(3M) 2.88MPrice $189.23
IPO 2020/2/13Option/Short Yes/YesTrades 15765Volume 1,232,368Change 0.25%
Quarterly earnings trend SEC filings · USD
24.3
24.6
24.9
24.12*
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-454M (YoY -113%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Revolution Medicines Inc (RVMD) Investment Analysis

What kind of company is Revolution Medicines Inc?

레볼루션 메디신즈(RVMD) 초고성장주
Healthcare · Biotechnology
Top 378 by Market Cap — Large-Cap

🧪 Revolution Medicines is a US late-stage clinical oncology biotech company developing novel cancer drugs targeting RAS proteins. The company operates a clinical pipeline targeting a range of solid tumors — including pancreatic, colorectal, and lung cancers — built on its RAS(ON) inhibitor platform. Its lead candidate, daraxonrasib, has reported meaningful overall survival improvement results in a Phase 3 clinical trial.

Learn more about Revolution Medicines Inc →
Market Cap
$40.2B
Approx. KRW 55.1 trillion
⚖️ 14% of Samsung Electronics
Market Cap Rank378
Employees883people
IPO2020/02/13
Current Price$189.23 ≈ 259,245원
NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 6일 (수) · 장 마감 후 EPS -24.8% 매출 -100.0%
🔔 Earnings release 2026년 2월 25일 (수) · 장 마감 후 EPS -17.6% 매출 -100.0%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-76.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-59.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-71.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.29
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
6.80
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
6.80
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$207.16
현재가 대비 +9.5%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
+33.0%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+44.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility
Frequently misses analyst estimates
0
예상 상회
0
예상 부합
2
예상 하회
0%
상회 비율
-21.9%
평균 서프라이즈
2026.05.06
하회
실적 $-2.29 · 예상 $-1.83 -25.0%
2026.02.25
하회
실적 $-1.86 · 예상 $-1.56 -18.9%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-32.9%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 대형주 Median 47.1% · Bottom tier
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+33.0%
양호
My positionMid-range
Low range Average High range
초고성장주 대형주 Median 32.1% · Top 49%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+44.9%
양호
My positionMid-range
Low range Average High range
초고성장주 대형주 Median 36.4% · Top 34%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-24.5%
부진
My positionBottom 25%
Low range Average High range
초고성장주 대형주 Median 1.0% · Bottom 22%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-29.1%
매우 부진
My positionBottom 5%
Low range Average High range
초고성장주 대형주 Median 11.8% · Bottom tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Outperformed the market by 486%p over 5 years
RVMD +553.9% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
+485.9%p
well ahead of the market
vs Health Care (XLV)
+530.2%p
well ahead of the sector average
1-year basis
vs S&P 500
+391.9%p
well ahead of the market
vs Health Care (XLV)
+388.7%p
well ahead of the sector average
Rank among peers
5-year return Top among peers Based on 24 peers
1-year return Top among peers Based on 24 peers
Current position within 52-week range
Low (-456.6%p) High (-2.4%p)
Current price is 456.6% above the 52-week low and 2.4% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-13.7%
Annualized volatility
64.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-24
Uptrend zone

Current price $189.23 above the midline ($186.49). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-24
Neutral zone — weak trend

MACD 5.216 · Signal 6.361 · Hist -1.146. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-24
Bullish zone

RSI 61.9 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 74.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Assets
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
25.25x
✓ Pricey
My positionBottom 25%
Low range Average High range
Biotechnology 대형주 median 7.26x · Bottom 19% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
Analyst target price (reference)
$207.16 vs. current price +9.5%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 대형주

Who owns it?

Ownership flow shows some pressure
Insider modest net selling -1.7% · Institutional modest net selling -0.3% · Short interest moderate 6.8% · Short interest fell -1.4%p over the last 90 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-1.7%
Insiders net selling
🏦 Institutions (funds & investors)
-0.3%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 86.3%
Institution-led, stable structure
Healthcare 대형주 Median 91.9%
🧑‍💼 Insiders 10.6%
Founder/management large holders (strong skin-in-the-game)
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated) 3.1%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
6.8%
Moderate
Healthcare 대형주 Median 3.6%
Past 90 days 📉 -1.4%p decrease
Short interest days to cover
4.5 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 200.2M주
Float (tradable shares) 190.1M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding RVMD

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
RVMD This Stock
$40.2B- 25.3 -76.67% - +0.3%
LLY
$1.13T43.0 36.2 107.64% 0.58% +0.9%
JNJ
$634.1B30.5 7.5 25.74% 2.04% +1.6%
ABBV
$458.2B127.9 - 15221.82% 2.65% +0.9%
UNH
$382.1B27.1 3.9 12.49% 2.15% -0.7%
MRK
$323.7B36.9 7.1 18.97% 2.49% +0.5%
Sector Avg-25.82.7-48.83%1.25%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 레볼루션 메디신즈(RVMD)?

레볼루션 메디신즈(RVMD) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of RVMD?

The market cap of RVMD is approximately $40.2B, ranking 378 within its sector.

What is the 52-week high and low for RVMD?

RVMD has recorded a 52-week high of $193.82 and a low of $34.00.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.